ArticleVirus genes2026
Investigating the antiviral effects of Timosaponin BII on enterovirus A/B via network pharmacology and experimental validation.
Article in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Enterovirus A/B is a significant pathogen responsible for a wide range of human diseases. Currently, effective preventive and therapeutic strategies against these viruses remain limited. Timosaponin BII is the active ingredient of a natural product with potential antioxidant and anti-inflammatory properties. This study aims to investigate the antiviral activity of Timosaponin BII and elucidate its underlying mechanism, thereby providing a scientific basis for the development of novel broad-spectrum anti-enterovirus agent. Firstly, systems pharmacology approaches were employed to integrate the potential targets of Timosaponin BII and predict its mechanism of action. Subsequently, the antiviral activity against representative strains of enterovirus A/B (EV-A71 for enterovirus A and CVB3 for enterovirus B respectively) was verified through cell morphology observation and CCK-8 assay in interferon-deficient Vero cells. Finally, the inhibitory effect on viral replication was assessed using a time-course drug addition experiment in non-interferon-deficient HeLa cells, and the inhibitory effect on viral proteins was detected by Western Blot. Timosaponin BII exhibited significant antiviral activity against enterovirus A and B at the cellular level, with EC
Indexed as
Identifiers
41642566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.